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Summary Mucositis may be a painful, debilitating, dose-limiting side-effect of both chemotherapy and radiotherapy for which there is no
widely accepted prophylaxis or effective treatment. The basis of management is pain relief, prevention of dehydration and adequate nutrition.
When tested vigorously, most antiseptic mouthwashes and anti-ulcer agents are ineffective. Simple mechanical cleansing by saline is the
most effective traditional measure. A variety of new agents are effective. Granulocyte macrophage colony-stimulating factor (GM-CSF) and
granulocyte colony-stimulating factor (G-CSF) act outwith the haemopoeitic system and can reduce mucositis, but the best schedule, dosage
and method of administration is not known or which is the best growth factor to prevent this side-effect. A placebo-controlled randomized trial
of antibiotic pastilles has shown a significant reduction in mucositis and weight loss during radiotherapy for head and neck cancer. Another
method to reduce radiation effects in normal tissue is to stimulate cells to divide before radiotherapy by silver nitrate or interleukin 1. These
methods may be particularly effective when given along with hyperfractionated radiation treatment such as CHART.
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Mucositis is a painful, debilitating, dose-limiting side-effect of
both chemotherapy and therapeutic irradiation of the head and
neck. The pathogenesis is straightforward: after chemotherapy or
during radiotherapy, cells in the basal layers of the mucous
membranes ofthe upper airways or upper digestive tact are unable
to replace adequately cells lost through inactivation or exfoliation.
Initially, there may be a transient white discoloration followed by
deepening erythema and later a white pseudomembrane, which
may be patchy or confluent. The most severe manifestation is
ulceration of the mucosa (Holmes, 1991). The resultant mucosal
damage may then be exacerbated by colonization of the affected
area by abnormal bacterial flora. Mucositis may be aggravated by
concomitant neutropenia and may be an important source of
systemic infection (Berkowitz et al, 1983).
Some degree of mucositis is inevitable when radical doses of
radiation are used to treat head and neck cancer. As a consequence,
eating can become difficult, with an average weight loss of 5 kg
during treatment (Symonds et al, 1996). Mucositis tends to occur
in the third week of treatment. When patients are treated with so-
called conventional-sized fractions of 2 Gy, mucositis can often
peak in the fifth to sixth week of treatment and, in spite ofcontin-
uing radiotherapy, mucositis can become less severe owing to
accelerated repopulation of normal tissues. Mucositis may lead to
premature end of a planned course of radiotherapy or a rest from
treatment. Both actions can lead to tumour persistence (Amdur et
al, 1989). The problem is particularly associated with accelerated
hyperfractionated regimens. Mucosal reactions tend to peak earlier
and are more severe but are of shorter duration than those after
conventional treatment (Saunders et al, 1996). As these regimens
are associated with improved local control, particularly in
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advanced disease (Horiot et al, 1997), any effective measure that
can reduce this side-effect will be very useful to patients treated by
twice or three times daily radiation regimens.
The problem is not restricted to radiation treatment. A whole
variety of chemotherapeutic agents can have effects upon the
oropharyngeal mucosa, including 5-fluorouracil with or without
folinic acid, interferon, methotrexate, bleomycin, doxorubicin and
epirubicin, cisplatin, vinblastine and the taxanes. Mucositis may be
the dose-limiting toxicity with a variety of regimens. As many as
80% of patients receiving 5-fluorouracil and folinic acid may
develop mucositis and, in up to 26%, this may be severe (Poon et al,
1989). Ulceration of the oropharynx with consequent dysphagia
reaches its peak 10 or so days after chemotherapy. Concomitant
neutropenia may encourage secondary colonization of the mouth
with a wide variety ofGram-negative and anaerobic bacteria along
with fungi, particularly Candida albicans. The problem is particu-
larly marked during bone marrow transplantation. Stomatitis,
secondary to myelosuppressive doses ofchemotherapy, can not only
be very painful and debilitating but may be the source oflife-threat-
ening sepsis. The origin of septicaemias is the mouth in 25-50% of
immune-suppressed patients (Epstein et al, 1992). Almost all cases
ofsystemic candidiasis originate from the oral cavity.
There is not a standard, widely accepted treatment to prevent
or ameliorate chemotherapy- or radiation-induced mucositis.
Traditionally, a range of remedies have been available to treat the
acute side-effects of cancer treatment within the mouth and the
pharynx. Only recently have some ofthese treatments been assessed
rigorously and found to be wanting. However, there is a new range
ofnovel therapies that alone or in combination can markedly reduce
dose-limiting side-effects and improve the quality oflife.
TRADITIONAL REMEDIES
Many traditional treatments are ineffective. However, the baby
should not be thrown out with the bath water. The basicprinciples of
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mouth care stand the test of time. They are to relieve pain, prevent
dehydration and provide adequate nutrition and deal with any focus
of infection, such as obvious candidiasis. Good dental hygiene is
paramount and the toothbrush is invaluable in reducing oral infec-
tion. Caries should be treated before anti-cancer treatment. A variety
of mouthwashes are strongly recommended, often without any
evidence to support this recommendation. Traditional remedies,
such as glycerine and thymol and glycerine and lemon, are not
effective (Hatton-Smith, 1994). Sodium bicarbonate mouthwashes
can be harmful if too concentrated by altering oral pH (DeWalt and
Haines, 1969), and hydrogen peroxide has been shown to be no
more effective than a saline mouthwash (Feber, 1996). The anti-
septic, chlorhexidine, and benzydamine, a non-steroidal inflamma-
tory agent with anaesthetic and antimicrobial properties, are popular
in the treatment of mucositis. However, neither have been shown to
be effective. Patients receiving radiation therapy were randomized
in a double-blind fashion to receive either chlorhexidine or a
placebo mouthwash. The trend was for more mucositis and more
toxicity in the chlorhexidine arm of the study. In this arm, more
patients complained of mouthwash-induced discomfort, taste alter-
ation and teeth staining. Owing to the degree of toxicity, it was felt
that chlorhexidine was actually detrimental (Foote et al, 1994).
Chlorhexidine and benzydamine have been compared in a
randomized trial, and there was no difference in either pain relief
or mucositis. Altogether, 92% of the patients using benzydamine
complained of pain in the mouth when using the mouthwash, and
50% refused to continue to use benzydamine (Samaranayake et al,
1988). A controlled trial of this agent compared with a placebo
(10% alcohol) claimed that radiation mucositis was reduced.
However, the benzydamine had to be diluted, and the local anaes-
thetic lidocaine was given in addition. The patients also received a
variety of systemic analgesics that were not allowed for in the
analysis (Epstein et al, 1989).
A three-arm trial in leukaemic patients of chlorhexidene vs
chlorhexidine and nystatin showed plain saline to be as effective as
the other two agents (Epstein et al, 1992). The nystatin may have
been rendered ineffective by the chlorhexidine, as the combination
has been shown to form a low-solubility salt. The minimum
inhibitory concentration for candida is higher for the combination
than for either drug alone (Barkvoll and Attramadal, 1989).
The message from all of these studies is that frequent mechan-
ical cleansing of the mouth by a simple saline solution is the most
effective measure, and more sophisticated mouthwashes may be
positively harmful.
ANTI-ULCER AGENTS
In severe mucositis, the mucous membrane can ulcerate; therefore, a
logical approach was to test the use of agents that promoted the
healing of ulcers and coated the mucous membrane to prevent
further damage. Such an agent is sucralfate. This drug was first used
to treat duodenal ulcers. It forms a potential barrier on damaged and
normal mucosa and is largely unabsorbed. A phase 2 study of this
disulphated disaccharide in combination with fluconazol suggested
that mucositis with associated pain could be reduced markedly
(Allison et al, 1995). However, randomized controlled trials (Barker
et al, 1991; Makkonen et al, 1994; Epstein and Wong, 1994) have
not shown that this agent prevents mucositis. It may, nevertheless,
reduce oral discomfort to a limited extent.
Other anti-ulcer agents have been tried. Pentoxifylline has been
found to be useful in the treatment of chronic trophic leg ulcers.
However, a double-blind randomized placebo-controlled crossover
trial did not show any effect in preventing mucositis in patients
treated with cisplatin and 5-fluorouracil (Verdi et al, 1995).
Another agent, azelastine, has been shown to produce clinical
improvement in aphthous ulcers and Behqet's disease. Those
treated with radiotherapy, peplomycin and fluorouracil were treated
with either azelastine, vitamin C, vitamin E and glutathione or the
same regimen minus the azelastine. There is a suggestion that the
addition of azelastine reduced mucositis (Osaki et al, 1994).
Feeding experimental animals additional glutamine seems to
reduce the effects of cytotoxic agents, particularly 5-fluorouracil
and methotrexate (O'Dwyer et al, 1987; Fox et al, 1988). Bowel
ulceration caused by these anti-metabolites and corresponding
bacteraemia was reduced (Fox et al, 1988). However, when addi-
tional glutamine supplements were given to patients suffering
from gastrointestinal cancer, treated by 5-fluorouracil and folinic
acid in a placebo-controlled double-blind trial, there was no differ-
ence in the degree of observed oral mucositis (Jebb et al, 1994).
Prostaglandins are cytoprotective compounds especially in the
gastrointestinal tract. Topical applications have been shown to lead
to healing of chronic leg ulcers (Eriksson et al, 1986). Intra-orally
applied prostaglandin E, is not significantly absorbed (Matejka et
al, 1990) but may reduce mucositis. Two very small, non-random-
ized studies claim a reduction in mucositis after both radiotherapy
(Sinzinger et al, 1989) and chemotherapy (Kuhrer et al, 1986).
Granulocyte and granulocyte macrophage
colony-stimulating factors
Granulocyte colony-stimulating factor (G-CSF) and granulocyte
macrophage colony-stimulating factor (GM-CSF) belong to a
family of glycoprotein growth factors, which promote the prolifer-
ation and differentiation of neutrophil and monocyte/macrophage
precursors and enhance the effector functions of mature
neutrophils in vitro and in vivo. They are produced by stromal
cells within the haemopoietic microenvironment (fibroblasts and
endothelium) and by immunocompetent cells (T cells and
macrophages). The action of these glycoproteins was thought to be
restricted initially to haemopoietic cells only, but laboratory
studies have shown that both G-CSF and GM-CSF influence the
migration and proliferation of human endothelial cells, suggesting
that these cytokines may act as regulatory signals outside the
haemopoietic system (Bussolino et al, 1989). Clinical experience
has also shown that these regulating proteins could stimulate the
cells of the mucous membranes of the oropharynx. Twenty-seven
patients with transitional cell carcinoma of the urogenital tract
were treated with methotrexate, doxorubicin, vinblastine and
cisplatin and were given G-CSF to reduce chemotherapy-induced
neutropenia. Not only was there a reduction in the degree of
neutropenia, but chemotherapy-induced mucositis was signifi-
cantly reduced. Some 44% of patients who did not receive G-CSF
developed mucositis compared with 11% of patients who had G-
CSF during the first or second cycles ofchemotherapy (P = 0.041)
(Gabrilove et al, 1988). Mucositis secondary to high-dose cytara-
bine and mitoxantrone used to treat refractory non-Hodgkin's
lymphoma was reduced when patients received GM-CSF. As well
as the expected reduction in severe neutropenia, the incidence of
mucositis was reduced from 60% in those patients not receiving
GM-CSF to 17% with GM-CSF (Ho et al, 1990).
Mucositis is a particularly troublesome problem in patients
receiving bone marrow transplantation. The incidence of
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mucositis can be as high as 100% in those receiving myeloablative
chemotherapy and can be severe (grades 3 and 4) in 82% (Wardley
and Scarffe, 1996). The severity ofmucositis was reduced by GM-
CSF in patients receiving thiotepa, total body irradiation and
etoposide before bone marrow transplantation (Spadinger et al,
1994). A similar reduction in the severity of mucositis was seen
after G-CSF in patients treated with cyclophosphamide, carmus-
tine and etoposide before autologous bone marrow transplantation
for Hodgkin's disease (Taylor et al, 1989). GM-CSF markedly
reduced the incidence of stomatitis secondary to radiotherapy in
patients receiving double half-body irradiation for refractory
myelomatosis (Troussard et al, 1995). Patients receiving GM-CSF
had only grade 1 stomatitis in comparison with previously treated
patients, all of whom developed grade 3 or 4 stomatitis without the
colony-stimulating factor. These phase 2 studies led to a series of
randomized controlled trials. A total of 109 patients suffering
from Hodgkin's disease, non-Hodgkin's lymphoma, a variety of
leukaemias and myeloma were treated with myeloablative
chemotherapy followed by an HLA-matched identical sibling
marrow transplant. Fifty-three patients received GM-CSF, the
other 56 received a placebo. There was a significant reduction in
both grade 3 and 4 mucositis and infection in the GM-CSF-treated
arm (Nemunaitis et al, 1995). A Japanese study (Katano et al,
1995) of only 14 patients receiving intra-arterial doxorubicin with
or without G-CSF suggested that oral mucositis secondary to
doxorubicin can be reduced or prevented by this cytokine.
A study of patients receiving chemotherapy for advanced head
and neck cancer was particularly interesting and gave new
information about the actions of GM-CSF. The response rates of
regimens containing cisplatin, 5-fluorouracil and folinic acid for
advanced head and neck cancer are high, but mucositis tends to be
the dose-limiting toxicity. Twenty patients with stage 4 squamous
carcinoma received cisplatin 20 mg m-2 daily, 5-fluorouracil
800 mg m-2 and folinic acid 90 mg m-2 by continuous infusion
over 96 h every 3 weeks. They were randomized to receive subcu-
taneous GM-CSF on days 5-14 after either the first or the second
cycle of chemotherapy. Each patient therefore acted as their own
control in this crossover study. After the first cycle of
chemotherapy, the patients treated with the GM-CSF had a
markedly reduced incidence oforal mucositis compared with those
not receiving the growth factor. The incidence of severe mucositis
was reduced when GM-CSF was given during the second cycle of
chemotherapy. Interestingly, those patients who received GM-CSF
with the first cycle of chemotherapy only appeared to have
continued benefit from the colony-stimulating factor with reduc-
tion of mucositis in the second cycle of chemotherapy. This study
goes some way to showing the mechanism of action of GM-CSF
upon the oral mucosa. Patients with prolonged periods of
neutropenia after chemotherapy are more likely to develop
mucositis. The critical neutrophil count appears to be in the order
of 1 x 109 1-1. The particular regimen of chemotherapy used in this
study was fairly non-myelotoxic, and no patients had neutrophil
counts falling below the critical level of 1 x 1091-'. The incidence
and severity of neutropenia was the same in patients with or
without GM-CSF. The reduction of oral mucositis by GM-CSF in
this study did not appear to be related to the granulocyte-stimula-
tory action ofthe growth factor. The inference is that the GM-CSF
had a direct effect upon the oral mucosa (Chi et al, 1995).
There have been a number of negative studies in which the
degree of mucositis has not been reduced by haemopoietic growth
factor support. The degree of severe neutropenia was reduced when
patients received G-CSF along with VAPEC-B chemotherapy
(Pettengell et al, 1992) for non-Hodgkin's lymphoma. A greater
dose intensity ofchemotherapy could be given to these patients, but
severe mucositis was the dose-limiting toxicity. Again, neutropenia
was reduced when patients with advanced breast cancer received
G-CSF along with 2-weekly high-dose doxorubicin and cyclo-
phosphamide (Ferguson et al, 1993), but almost half the courses
of chemotherapy were complicated by moderate to severe oral
mucositis. The degree of mucositis was similar to historical
controls in ten patients receiving HLA identical sibling marrow
transplants for lymphoid malignancy, pretreated with high-dose
busulphan and cyclophosphamide (Atkinson et al, 1991).
Subcutaneous GM-CSF was given from day 7 to day 13 after trans-
plantation. Interestingly, the incidence of graft vs host disease was
worse in those patients receiving GM-CSE
In all of these studies, the haemopoietic stimulating factor has
been given either subcutaneously orintravenously. Currently, trials
are underway with GM-CSF mouthwashes in patients receiving
myeloablative chemotherapy (Wardley and Scarffe, 1996) and in
the treatment of radiation mucositis both at the Radiumhemmet
and in Greece (Throuvalas et al, 1995).
ANTIBIOTICS
The oropharyngeal bacterial flora consists mainly of anaerobic
bacteria, a lesser number of viridans streptococci and Neisseria
species. Irradiation and local tumour surgery both interfere with
the mucosal defences important for the maintenance of a micro-
biological balance. After surgery, there may be impaired motility
of normal structures, and grafts may still be healing with areas of
necrotic tissue, which may be colonized by abnormal bacterial
flora. Necrotic tumour is a very good growth medium for many
bacteria. Radiotherapy can encourage bacterial overgrowth in two
ways. The first is by damaging and killing rapidly dividing cells in
the oropharynx, leading to ulceration and colonization by
abnormal bacteria. Saliva production may be reduced, as one or
more parotid glands are often within the radiation field. Saliva
washes away intraoral debris, food particles and bacteria and
contains immunoglobin A, all factors important in the mainte-
nance of normal mucosal bacterial flora. It has been suggested that
micro-organisms, particularly aerobic Gram-negative bacteria,
play a role in irradiation mucositis (van Saene and Martin, 1990).
Although such bacteria are present in only very small numbers in
healthy subjects, a Gram-negative bacillary carriage rate of 57%
was found in patients before irradiation (Spijkevet et al, 1989).
The frequency ofbacillary carriage in this group ofpatients led the
same group to try a novel approach to the problem (Spijkevet et al,
1991). Lozenges containing polymyxin E, tobramycin and ampho-
tericin B were given to a group of 15 patients treated by radio-
therapy for head and neck cancer. Mucositis was confined to
erythema only in these patients. A much larger placebo-controlled
double-blind trial of similar antibiotic pastilles (Symonds et al,
1996) showed a clinically beneficial effect, although less striking
than the smaller study of Spijkevet. A total of 275 patients
suffering from T1-T4 head and neck cancer were entered into the
study. Of these, 136 patients were allocated to suck four times
a day a pastille containing amphotericin B, polymyxin and
tobramycin. The remaining 139 patients received an identical
placebo. Bacteriological monitoring was carried out before and
twice weekly during treatment. Both arms of the study were well
balanced for T and N stage, age, sex and radiation dose (60 Gy).
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There was a reduction in mucositis distribution (P = 0.002),
mucositis area (P = 0.028), dysphagia (P = 0.006) and, especially,
weight loss (P = 0.009), which is a highly objective end point.
There was a clear tendency for patients with positive cultures for
aerobic, Gram-negative bacteria (P = 0.003) and yeasts (P =
0.026) during treatment to have more severe mucositis. The active
pastilles reduced the percentage of patients with yeast cultures (P
= 0.003) but had less effect on aerobic Gram-negative bacteria.
A smaller study from the Mayo Clinic of similar antibiotic
lozenges showed no difference in mucositis scores measured by a
nurse or radiation oncologist, but the mean patient mucositis score
and the duration of patients reporting grade 3 and 4 mucositis were
both lower in the antibiotic lozenge arm of the study (P = 0.02 and
0.007 respectively) (Okuno et al, 1997).
In patients receiving allogenic bone marrow transplantation, up
to 64% of septicaemias originate from oral infection (Donnelly et
al, 1992). As in the case of patients with oral cancer, immunosup-
pressed patients have an increased frequency ofcarriage of aerobic
Gram-negative bacteria and fungi (Woo et al, 1993). The use of
prophylactic antibiotics (Meissenberg et al, 1996) certainly
reduces the incidence of fever and bacteraemia in this group of
patients, but the impact on mucositis is less well documented.
Intuitively, one would expect systemic antibiotics to have some
effect on mucositis.
NOVEL AGENTS
Capsaicin, the active ingredient in chilli peppers, has been shown
to provide temporary pain relief in 11 patients with oral mucositis
secondary to either chemotherapy or radiotherapy (Berger et al,
1995). The vehicle for the capsaicin was candy, and the authors list
their own 'taffy' recipe. These patients took two to six candies a
day for continuous pain relief. One problem with capsaicin is an
initial burning sensation in the mouth. This was dealt with by
giving concomitant benzocaine.
Ice in the mouth can cause local vasoconstriction and may reduce
the uptake of 5-fluorouracil into mucosal cells. As the plasma half-
life ofthis drug is short (5-20 min), patients were asked to suck ice
chips for 5 min before and 30 min after 425 mg m-25-Fu along with
folinic acid 20 mg m-2 i.v. given for 5 days. A total of 95 patients
were randomized to suck ice or to serve as a control group during
the first cycle ofchemotherapy and subsequently crossed over in the
next cycle. Mucositis was reduced significantly (P = 0.002). Apart
from numbness ofthe mouth and 'ice cream' headaches, the ice was
well tolerated (Mahood et al, 1991).
A follow-on study (Rocke et al, 1993) showed that using ice for
60 min offered no extra protection. Ice packs have also been shown
to reduce 5-Fu-induced ocular irritation (Loprinzi et al, 1994).
Melphalan-induced stomatitis may also be prevented by
cryotherapy. In a series of 18 patients, only one developed grade 3
mucositis when ice pops were sucked 5 min before and stopped
5 min after a melphalan infusion (140-180 mg m-2 over 30 min)
before marrow transplantation (Meloni et al, 1966).
At the start of a course ofradiotherapy treatment, a considerable
number of cells within the basal layer of the buccal mucosa are not
undergoing division. Initially, there may be a decrease in mitotic
activity, leading to the retention of superficial cells, which appear
white owing to the greater degree of keratinization. Radiation-
induced leukoplakia is one ofthe earliest changes affecting the oral
cavity, especially the mucosa and dorsum of the tongue (Fine,
1974). As more cells are shed from the mucosa, the rate ofdivision
of the basal layer increases rapidly to replace cell loss (Holmes,
1991). During the first week of radiotherapy, there may be a
discrepancy between cell proliferation and cell killing. This is espe-
cially true in patients receiving hyperfractionated accelerated radio-
therapy. It has been suggested that cell production could be
stimulated before radiotherapy by the use of silver nitrate. Sixteen
patients suffering from advanced oral cancer were treated by accel-
erated hyperfractionation. This was a split-course schedule of
1.6 Gy twice daily five times a week initially, to a total dose of
32 Gy. After a gap of 9-12 days (depending on the severity and
healing of acute mucositis), patients were treated again twice daily
to a total dose of 66-74 Gy. Five days before radiotherapy and for
the first two days of treatment, the left side of the patient's mouth
was brushed with 2% silver nitrate three times a day after meals,
and the right side was left untreated to act as a symmetrical indi-
vidual control. The degree of mucositis appeared to be greater on
the untreated side of the mouth. Most patients had confluent
mucositis by the end ofthe first part ofthe radiotherapy in this area.
By comparison, the reaction was no worse than severe erythema in
the silver nitrate-treated area (Maciejewski et al, 1992).
One of the methods by which GM-CSF may stimulate oral
mucosal cells is by enhancing interleukin 1 (IL-1) transcription
and translation (Dinarello, 1991). Interleukin I has been shown to
convey substantial protection to normal cells against the lethal and
sublethal effects of whole-body irradiation, extensive chemo-
therapy and localized irradiation in experimental animals
(Zaghloul et al, 1994). It has been suggested that the cytoprotec-
tive effects may result from increasing proliferation rates in
mucosal cells. It has been shown particularly in experiments on
irradiated mice in which pretreatment with IL-1 increased the
thymidine labelling index particularly in the lip, tongue and crypt
cells of the duodenum in irradiated mice. It is possible that local
applications of IL-1 may increase proliferation rates before radio-
therapy. It has been shown that endogenous IL-I has the ability to
trigger endogenous production of this substance in the epithelial
cells cultured in vitro, which in turn can lead to higher levels of
circulating IL-I (Warner et al, 1987).
Pilocarpine
A late oral complication of high-dose radiotherapy is xerostomia.
Following irradiation of usually both parotid glands, there is
permanent impairment of salivary production. As a consequence,
there is marked susceptibility to dental caries and oral infections.
Speaking, chewing and swallowing are more difficult. There is no
effective means of treating a dry mouth secondary to salivary
gland dysfunction (Fox et al, 1991), and many patients carry a
small bottle of water.
Pilocarpine is a parasympathetic stimulant of exocrine secre-
tion. Two placebo-controlled double-blind trials have shown the
value of this alkaloid (Johnson et al, 1993; LeVeque et al, 1993).
Both multicentre studies were similar in design and contained 207
and 162 patients respectively. At least one parotid gland had been
irradiated to doses above 40 Gy, but patients had to have some
evidence of residual salivary function. Salivary production was
measured and symptoms were assessed by a visual analogue scale.
In both studies, pilocarpine improved symptoms compared with
a placebo, but in only one (LeVeque et al, 1993) was salivary
production increased to a statistically significant degree, although
the volume increase was small. It is possible that qualitative differ-
ences in saliva production rather than quantitative differences
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helped to improve symptoms, particularly production of more
mucin, which is a more long-lasting lubricant and mucosal wetting
agent. A dose of 5 mg three times daily was effective in most
patients, and adverse effects were usually limited to increased
sweating.
CONCLUSION
Many of the traditional remedies for mucositis can be discarded as
they have been shown to be ineffective or even harmful. The most
effective measure is frequent oral rinsing with a bland mouthwash,
such as saline, to reduce intraoral bacteria. Good dental hygiene
is essential. The importance of the reduction of plaque and the
control of periodontal disease is often forgotten. Before radio-
therapy of the head and neck or, for that matter, chemotherapy
likely to produce mucositis, such as before bone marrow trans-
plantation, treatment ofpre-existing caries and the removal of any
pre-existing calculus is vital, as pre-existing dental infection can
be a potent source of systemic infection. Even in health, bacter-
aemia after oral and dental procedures is not at all uncommon
(McElroy, 1984). Patients should be encouraged to use a soft
toothbrush and to use dental floss regularly.
Topical non-absorbable antibiotics do appear to reduce the
unpleasant sequelae of radiation treatment for head and neck
cancer, although neither the optimal type of antibiotics nor the
method of administration has been worked out. Use of antibiotic
pastilles was strikingly less effective in the reduction of aerobic
Gram-negative bacteria than when the same antibacterials were
applied as a gel or a paste to the buccal mucosa in intensive care
patients, when aerobic Gram-negative bacteria were reduced dras-
tically within 3-4 days (Stoutenbeek et al, 1984; Ledingham et al,
1988). There seems to be a need for new formulations to allow the
protracted delivery of antimicrobials to the oropharynx in patients
receiving therapeutic irradiation.
Interleukin 1 and silver nitrate appear to improve the tolerance
of experimental animals and patients with head and neck cancer,
respectively, to radiotherapy by increasing the number of cycling
cells before this treatment. Both GM-CSF and G-CSF probably act
in the same way in the case of radiation treatment. The precise
timing of these colony-stimulating factors in the case of
chemotherapy is much more problematical and may well depend
on the agents used and the schedule in which they are given.
Mucositis is usually the dose-limiting toxicity ofpatients receiving
5-fluorouracil and folinic acid. They were given concomitant G-
CSF (5 ,ug kg-' day-' subcutaneously for 14 days) along with 5-
fluorouracil (425 mg/m-2) and folinic acid (20 mg m-2) for 5 days
repeated every 28 days. Four out offive assessable patients treated
with this regimen developed grade 4 myelosuppression. Other
patients were treated with the same regimen but the G-CSF admin-
istration began 24 h after the last dose of 5-fluorouracil. None of
these patients developed neutropenia. It was felt that the
concurrent administration of the haematological growth factor
was responsible for the increased toxicity of chemotherapy.
Interestingly, although the aim of the study initially was to see if
mucositis could be reduced by this approach, the authors do not
comment on the degree of mucositis in treated patients in their
publication (Meropol et al, 1992). The scheduling of the cytokine
could be responsible for either the success or the failure in
preventing mucositis. Chi and colleagues (1995) illustrated a
marked reduction in chemotherapy-induced mucositis in a
crossover study. The chemotherapy was given over 5 days and
repeated every 3 weeks with GM-CSF beginning at the end of
chemotherapy. The two studies that stand out as showing a negative
effect for mucositis reduction by G-CSF have similar characteris-
tics. In both, intensive chemotherapy was given frequently along
with G-CSF. The first is a study of VAPEC-B chemotherapy in
which doxorubicin in combination with cyclophosphamide or
etoposide was given every 2 weeks. In between, vincristine and
bleomycin were administered. Bleomycin in particular can be quite
toxic to the oral mucosa (Pettengell et al, 1992). In the other study,
doxorubicin (100 mg m-2) or doxorubicin and cyclophosphamide
were given at 2-weekly intervals (Ferguson et al, 1993). A 10-day
course of G-CSF was started 24 h after each cycle of
chemotherapy. The VAPEC-B patients received daily subcutaneous
G-CSF for up to a week preceding and for up to 2 weeks after treat-
ment with doxorubicin, cyclophosphamide and etoposide. The
combination of the cytokine and the chemotherapy seemed to have
a definite beneficial effect upon the neutrophil count but may not
be optimal for preventing mucositis. Most studies of the cytokines
have been directed towards their effect upon the haemopoietic
system, and dosages and schedules are usually tailored accordingly.
The optimal doses for preventing mucositis are not known; neither
is the method of delivery (subcutaneous or intravenous) and the
duration and timing oftreatment. It is not known which is the supe-
rior cytokine, either G-CSF or GM-CSF.
The use of GM-CSF mouthwashes is an intriguing develop-
ment. On the little evidence available, perhaps such mouthwashes
should be administered before fractionated radiotherapy in order to
promote cell division, so that cell replication in the mouth can keep
up with cell killing by radiotherapy. The timing of the use of
mouthwashes with chemotherapy is far less clear and would seem
to depend on the type of chemotherapy and how frequently these
agents are given. It is possible that stimulation of mucosal cells to
divide renders them more vulnerable to chemotherapy.
The greatest scope for reduction of mucositis is during acceler-
ated hyperfractionated radiotherapy, such as the MRC CHART
regimen. In this study, there was a trend for improved local control
ofadvanced tumours, particularly laryngeal cancer (Saunders et al,
1996). Acute skin reactions were less than with conventional
regimens, as was late treatment-related morbidity.
If acute mucositis could be reduced, a higher radiation dose
could be given, leading to better local control and survival.
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